Envafolimab Biosimilar, PD-L1 Monoclonal Antibody-远泰生物

提醒成功

QQ登录

微信登录

同意并阅读使用条款和隐私策略

账号密码登录

微信/QQ登录

没有账号？立即注册

搜索

抗体销售咨询健康评估咨询 mRNA-LNP咨询

0731-88388787

首页 > 产品中心 > 产品详情

产品规范
Type	In Vivo - Reseach Grade Antibody
Host	CHO cells
catalog#	B00056
Application	Flow cytometry, animal model study
Aliases	KN035, KN035-Fc, VHH-Fc Fusion Protein, PD-L1 Nanobody
Size/Concentration	1mg/5mg/20mg
Isotype	Human IgG1 Fc
Storage	Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.
Species Reactivity	Human
Immunogen	Human PD-L1
Formulation	PBS, pH 7.4

Description
What is envafolimab biosimilar research grade? Envafolimab is a humanized nanobody (VHH-hIgG1 Fc fusion protein) directed against the human protein ligand PD-L1, with potential immune checkpoint inhibitory and antineoplastic activities. Envafolimab biosimilar uses the same protein sequences as the therapeutic antibody envafolimab. PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Envafolimab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body’s adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.

Description

What is envafolimab biosimilar research grade? Envafolimab is a humanized nanobody (VHH-hIgG1 Fc fusion protein) directed against the human protein ligand PD-L1, with potential immune checkpoint inhibitory and antineoplastic activities. Envafolimab biosimilar uses the same protein sequences as the therapeutic antibody envafolimab. PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Envafolimab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body’s adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.

Envafolimab Biosimilar, PD-L1 Monoclonal Antibody B00056

规格：

1mg
5mg
20mg

数量：

说明书：

¥3250

~~¥3250~~

加入购物车

立即购买

咨询

ProMab Biotechnologies, Inc.

联系方式

CONTACT

联系电话:

0731-88388787
公司邮箱:

sales@promab.cn
公司地址:

湖南省长沙市高新开发区林语路239号顺畅产业园5楼
湖南省长沙市望城区普瑞大道8号出版科技园2号楼

官方微信

产品中心

Product

技术服务

service

客户留言

message